Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GREGORY J FELDMAN

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1710942305
CMS profile
214078
Location
COLUMBIA, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$14,199.78

181 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 2 of 4; records 51–100 of 181 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GREGORY J FELDMAN

NPI 1710942305 · CMS profile ID 214078

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

COLUMBIA, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 181 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1710942305?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GREGORY J FELDMAN, NPI 1710942305, CMS profile ID 214078. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 181 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1710942305?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). GREGORY J FELDMAN, NPI 1710942305, CMS profile ID 214078. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 181 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1710942305?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
GREGORY J FELDMAN, NPI 1710942305, CMS profile ID 214078, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 181 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1710942305?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

181 matching records · $14,199.78 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 181 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 181.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Electromed, Inc. $21.2909/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849602301 CMS
Philips Electronics North America Corporation $12.7209/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853235917 CMS
Grifols USA, LLC $13.6409/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 846771787 CMS
Janssen Pharmaceuticals, Inc $11.6509/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788600417 CMS
Mylan Inc. $1,861.0009/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965336653 CMS
Mylan Inc. $986.0009/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965336655 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $5.7708/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763342994 CMS
Electromed, Inc. $6.0108/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849602259 CMS
AstraZeneca Pharmaceuticals LP $13.0908/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829579547 CMS
Philips Electronics North America Corporation $11.9408/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853235915 CMS
Electromed, Inc. $19.1708/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849602227 CMS
Actelion Pharmaceuticals US, Inc. $18.3208/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788600423 CMS
Nabriva Therapeutics, plc $20.6108/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844883935 CMS
Paratek Pharmaceuticals, Inc. $14.8608/17/2021 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 813502115 CMS
Mylan Specialty L.P. $15.8508/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965427109 CMS
GlaxoSmithKline, LLC. $10.0908/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802988743 CMS
Novartis Pharmaceuticals Corporation $15.5108/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812676201 CMS
Mylan Specialty L.P. $13.9608/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965425975 CMS
Paratek Pharmaceuticals, Inc. $14.1908/02/2021 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 813502111 CMS
GlaxoSmithKline, LLC. $12.4407/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802943823 CMS
Takeda Pharmaceuticals U.S.A., Inc. $13.7507/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819924325 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $13.4207/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763342996 CMS
Actelion Pharmaceuticals US, Inc. $21.7307/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788600427 CMS
GlaxoSmithKline, LLC. $12.3307/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802952869 CMS
AstraZeneca Pharmaceuticals LP $15.3007/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829495025 CMS
Electromed, Inc. $21.9007/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849602117 CMS
GlaxoSmithKline, LLC. $14.1007/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802209199 CMS
Electromed, Inc. $26.2207/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849602087 CMS
GlaxoSmithKline, LLC. $11.8407/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801991055 CMS
Janssen Pharmaceuticals, Inc $16.4007/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788600411 CMS
AstraZeneca Pharmaceuticals LP $12.3907/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829765311 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.8207/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763342998 CMS
GlaxoSmithKline, LLC. $13.3407/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801687109 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.2207/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763343000 CMS
Janssen Pharmaceuticals, Inc $8.7306/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788600409 CMS
Electromed, Inc. $27.6806/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849602031 CMS
GENZYME CORPORATION $15.5906/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843432781 CMS
GENZYME CORPORATION $11.6306/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843432761 CMS
Mylan Specialty L.P. $21.2406/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965420343 CMS
GlaxoSmithKline, LLC. $12.2706/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803026745 CMS
Takeda Pharmaceuticals U.S.A., Inc. $16.3306/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819924323 CMS
AstraZeneca Pharmaceuticals LP $21.3406/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829883023 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $12.5506/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763343002 CMS
AstraZeneca Pharmaceuticals LP $13.0406/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829556025 CMS
Electromed, Inc. $21.3106/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849601967 CMS
Genentech USA, Inc. $24.3406/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835916017 CMS
AstraZeneca Pharmaceuticals LP $13.3406/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829393323 CMS
GlaxoSmithKline, LLC. $10.3906/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803055151 CMS
AstraZeneca Pharmaceuticals LP $12.7206/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829992915 CMS
Mylan Specialty L.P. $15.9206/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965418471 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $38,449.11 217
PY2020 $15,642.70 136
PY2021 $14,199.78 181
PY2022 $3,195.79 178
PY2023 $1,144.92 59
PY2024 $40.72 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $542,548.17 46
PY2024 Principal investigator $1,496,878.67 75
PY2023 Recipient $12,662.49 5
PY2023 Principal investigator $2,345,387.83 1,780
PY2022 Recipient $8,394.00 1
PY2022 Principal investigator $5,905,879.41 978
PY2021 Recipient $3,316.83 3
PY2021 Principal investigator $2,559,241.44 88
PY2020 Recipient $14,625.26 2
PY2020 Principal investigator $459,066.41 46
PY2019 Recipient $189.08 1
PY2019 Principal investigator $1,745,418.86 213

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

46 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Verona Pharma, Inc. $30,753.12 12/19/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891567
Principal investigator 1 PFIZER INC. $172.50 12/16/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS No dispute reported 06/30/2026 1228734005
Principal investigator 1 Verona Pharma, Inc. $61,933.28 11/19/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891565
Principal investigator 1 Verona Pharma, Inc. $883.20 11/14/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891589
Principal investigator 1 Verona Pharma, Inc. $82.80 11/14/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891591
Principal investigator 1 Verona Pharma, Inc. $10,000.00 11/12/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891611
Principal investigator 1 Verona Pharma, Inc. $1,852.00 11/12/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891613
Principal investigator 1 PFIZER INC. $3,051.00 10/23/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS No dispute reported 06/30/2026 1228733266
Principal investigator 1 Verona Pharma, Inc. $2,200.00 09/17/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891521
Principal investigator 1 SANOFI US SERVICES INC. $4,406.00 09/03/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226130638
Principal investigator 1 Verona Pharma, Inc. $2,200.00 08/27/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891515
Principal investigator 1 Verona Pharma, Inc. $3,000.00 08/20/2025 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891429
Principal investigator 1 SANOFI US SERVICES INC. $4,311.00 08/11/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226130603
Principal investigator 1 ModernaTX, Inc. $12,720.00 07/21/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007964
Principal investigator 1 SANOFI US SERVICES INC. $4,063.50 07/02/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226130476
Principal investigator 1 Currax Pharmaceuticals LLC $3,693.30 06/24/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717954
Principal investigator 1 Currax Pharmaceuticals LLC $3,110.25 06/13/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717609
Principal investigator 1 ModernaTX, Inc. $89,680.00 06/12/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007938
Principal investigator 1 ModernaTX, Inc. $334.00 06/12/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007942
Principal investigator 1 SANOFI US SERVICES INC. $13,493.50 06/09/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226130400
Principal investigator 1 ModernaTX, Inc. $160.00 06/05/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007954
Principal investigator 1 ModernaTX, Inc. $22,400.00 06/05/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007958
Principal investigator 1 ModernaTX, Inc. $1,815.00 06/05/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007960
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,000.00 06/04/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185546359
Principal investigator 1 AstraZeneca Pharmaceuticals LP $412.59 05/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A Phase II Randomized Double-blind Placebo controlled Study to Assess the Efficacy Safety and Tolerability of MEDI3506 in Participants with Moderate to Severe Chronic Obstructive Pulmonary Disease and Chronic Bronchitis FRONTIER 4 No dispute reported 06/30/2026 1185546361
Principal investigator 1 Currax Pharmaceuticals LLC $7,901.73 05/28/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717881
Principal investigator 1 SANOFI US SERVICES INC. $203.00 05/27/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226130396
Principal investigator 1 ModernaTX, Inc. $334.00 05/22/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007946
Principal investigator 1 ModernaTX, Inc. $152,000.00 05/22/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007956
Principal investigator 1 ModernaTX, Inc. $1,045.00 03/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007944
Principal investigator 1 ModernaTX, Inc. $3,325.00 03/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007962
Principal investigator 1 Currax Pharmaceuticals LLC $14,963.20 03/05/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717409
Principal investigator 1 PFIZER INC. $36,060.00 03/05/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1228796406
Principal investigator 1 ModernaTX, Inc. $668.00 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007940
Principal investigator 1 Currax Pharmaceuticals LLC $481.00 02/06/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717221
Principal investigator 1 Currax Pharmaceuticals LLC $962.00 01/30/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717197
Principal investigator 1 ModernaTX, Inc. $1,372.80 01/29/2025 Non-covered Recipient Entity
KEYSTONE RESEARCH LLC
A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive No dispute reported 06/30/2026 1252980920
Principal investigator 1 ModernaTX, Inc. $4,358.90 01/29/2025 Non-covered Recipient Entity
KEYSTONE RESEARCH LLC
A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive No dispute reported 06/30/2026 1252980922
Principal investigator 1 Eli Lilly and Company $10,294.00 01/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187892622
Principal investigator 1 ModernaTX, Inc. $6,270.00 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007948
Principal investigator 1 ModernaTX, Inc. $1,520.00 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007950
Principal investigator 1 ModernaTX, Inc. $2,004.00 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007952
Principal investigator 1 ModernaTX, Inc. $12,468.30 01/24/2025 Non-covered Recipient Entity
KEYSTONE RESEARCH LLC
A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive No dispute reported 06/30/2026 1252980918
Principal investigator 1 PFIZER INC. $1,000.00 01/15/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS No dispute reported 06/30/2026 1228800096
Principal investigator 1 Eli Lilly and Company $52.70 01/09/2025 Non-covered Recipient Entity
KEYSTONE RESEARCH LLC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187886244
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,537.50 01/08/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled 40-week Phase III Efficacy and Safety Study of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma No dispute reported 06/30/2026 1185546357